ALAN S MICHAELS
Engineering in Boston, MA

5938928, Aug 17, 1999

Sep 18, 1997

8/933148

Alan Sherman Michaels - Chestnut Hill MA

Nonap Pty. Ltd. - Victoria

B01D 6136, B01D 6100

210634

An osmotic concentration process for selectively extracting one or more volatile components from other components in a liquid mixture across a membrane structure which includes a semipermeable barrier film attached to a non-liquid-wettable microporous membrane is disclosed. The process includes the steps of: (a) contacting the liquid mixture with a surface of the semipermeable barrier film; (b) contacting a surface of the non-liquid-wettable microporous membrane with an extracting liquid in which one or more volatile components is soluble; and (c) collecting the remaining liquid mixture. As a result of the process the volatile component or components are extracted from the liquid mixture, passed through the membrane structure in a vapor phase and are dissolved in the extracting liquid. Also disclosed is a membrane arrangement for use in osmotic concentration of aqueous solution such as juice and other beverages, is constituted by a water-permeable sheet attached to a non-water-wettable microporous membrane. Preferably, the structure is in the form of a laminate in which the sheet is laid upon or bounded to the membrane.

5324775, Jun 28, 1994

Jul 2, 1992

7/907518

Woonza Rhee - Palo Alto CA
Donald G. Wallace - Menlo Park CA
Alan S. Michaels - Boston MA
Ramon A. Burns - Fremont CA
Louis Fries - Los Altos CA
Frank DeLustro - Belmont CA
Hanne Bentz - Newark CA

Collagen Corporation - Palo Alto CA

C08G 6348, C08G 6391, C08G 6340

525 542

Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding biologically inactive, natural, biocompatible polymer to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide biocompatible conjugates. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living (preferably human) being for the purpose of providing soft tissue augmentation.

5550188, Aug 27, 1996

Jun 7, 1995

8/478510

Woonza Rhee - Palo Alto CA
Donald G. Wallace - Menlo Park CA
Alan S. Michaels - Boston MA
Ramon A. Burns - Fremont CA
Louis Fries - Los Altos CA
Frank DeLustro - Belmont CA
Hanne Bentz - Newark CA

Collagen Corporation - Palo Alto CA

G02C 704, A61F 200

525 541

Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.

5002745, Mar 26, 1991

May 7, 1990

7/519607

Alan S. Michaels - Chestnut Hill MA
Wayne H. Lee - Pocatello ID
Theodore F. Munday - Kendall Park NJ

FMC Corporation - Philadelphia PA

C01B 2504

423322

A process is described for the separation and recovery of phosphorus from phosphorus-dirt mixtures by adding a quaternary ammonium compound to the mixture, while it is under an aqueous cover, agitating same, and separating a lower phosphorus phase from an upper dirt phase. The mixtures are treated prior to addition of the quaternary ammonium compound, where required, by lowering their dirt to phosphorus levels sufficiently low to permit them to be destabilized.

5413791, May 9, 1995

Feb 17, 1994

8/198128

Woonza Rhee - Palo Alto CA
Donald G. Wallace - Menlo Park CA
Alan S. Michaels - Boston MA
Ramon A. Burns - Fremont CA
Louis Fries - Los Altos CA
Frank DeLustro - Belmont CA
Hanne Bentz - Newark CA

Collagen Corporation - Palo Alto CA

A61F 200, A61F 1300, A61K 914, A61K 950

424422

Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.

5051236, Sep 24, 1991

Dec 19, 1988

7/286564

Alan S. Michaels - Chestnut Hill MA

FMC Corporation - Philadelphia PA

A23L 334

422 1

A process is provided for sterilizing or pasturizing aqueous fluids by contacting the aqueous fluid with a permeable membrane to separate the fluid into a serum and a residue, separating the serum into two portions, the pH of the first portion is increased and the pH of the second is decreased. The second portion of serum is combined with the residue, maintained at an elevated temperature to reduce the concentration of microbial cells, and combined with the first portion of serum to reconstitute the flowable fluid with a reduced concentration of viable cells.

5328955, Jul 12, 1994

Jul 30, 1992

7/922541

Woonza Rhee - Palo Alto CA
Donald G. Wallace - Menlo Park CA
Alan S. Michaels - Boston MA
Ramon A. Burns - Fremont CA
Louis Fries - Los Altos CA
Frank DeLustro - Belmont CA
Hanne Bentz - Newark CA

Collagen Corporation - Palo Alto CA

C08G 6348, A61F 1300, A61F 200

525 541

Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.

5817359, Oct 6, 1998

Oct 11, 1996

8/729181

Alan Sherman Michaels - Chestnut Hill MA
R. Philip Canning - Ontario, CA
Paul Hogan - Victoria, AU

Palassa Pty. Ltd. - Victoria

C12H 304, B01D 1104, B01D 6158

426425

The present invention provides methods and for the dealcoholization of alcohol containing solutions, especially fermented beverages. In preferred embodiments the methods employ a novel controlled-strip evaporative perstraction technique following initial clarification to remove biomass, wherein strip solutions, dealcoholized beverage, or both are recycled for use in the strip solutions for dealcoholization of subsequent batches of feed beverage. In further preferred embodiments additives are introduced into the strip solution to further limit loss of volatile components during perstraction. Biomass removed by the clarification is then returned to the retentate product following perstration.

5376375, Dec 27, 1994

Jan 5, 1994

8/177578

Woonza Rhee - Palo Alto CA
Donald G. Wallace - Menlo Park CA
Alan S. Michaels - Boston MA
Ramon A. Burns - Fremont CA
Louis Fries - Los Altos CA
Frank DeLustro - Belmont CA
Hanne Bentz - Newark CA

Collagen Corporation - Palo Alto CA

A61F 200, A61F 1300, A61K 914, A61K 950

424423

Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.

5162430, Nov 10, 1992

Nov 14, 1989

7/433441

Woonza Rhee - Palo Alto CA
Donald G. Wallace - Menlo Park CA
Alan S. Michaels - Boston MA
Ramon A. Burns - Fremont CA
Louis Fries - Los Altos CA
Frank DeLustro - Belmont CA
Hanne Bentz - Newark CA

Collagen Corporation - Palo Alto CA

C08G 6348, C08G 6391

525 541

Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.